Einloggen

Thematische Bibliographien / Maastricht III / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Maastricht III.

Zeitschriftenartikel zum Thema „Maastricht III“

Autor: Grafiati

Veröffentlicht am 5. April 2025

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Maastricht III" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

Sanchez-Izquierdo Riera, J. A., C. Cisneros Alonso, R. García Guijorro, J. C. Montejo González und A. Andrés Belmonte. „Donantes tipo III de Maastricht“. Medicina Intensiva 35, Nr. 8 (November 2011): 524–25. http://dx.doi.org/10.1016/j.medin.2011.06.001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Claessen, Jacques, Gwenny Zeles, Sven Zebel und Hans Nelen. „Bemiddeling in strafzaken in Maastricht III“. Tijdschrift voor Herstelrecht 15, Nr. 4 (Dezember 2015): 9–24. http://dx.doi.org/10.5553/tvh/1568654x2015015004003.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Perera, M. Thamara P. R. „The super-rapid technique in Maastricht category III donors“. Current Opinion in Organ Transplantation 17, Nr. 2 (April 2012): 131–36. http://dx.doi.org/10.1097/mot.0b013e3283510817.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Lemoine, L., L. Neron, A. Hamidi, A. Leon und J. P. Graftieaux. „Le Maastricht III : une modalité confidentielle de prélèvement d’organes ?“ Annales Françaises d'Anesthésie et de Réanimation 33 (September 2014): A230. http://dx.doi.org/10.1016/j.annfar.2014.07.388.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Arnaez, J., F. Gómez und S. Caserío. „Donación en asistolia controlada (tipo III de Maastricht) en pediatría“. Medicina Intensiva 41, Nr. 6 (August 2017): 386. http://dx.doi.org/10.1016/j.medin.2016.10.012.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Arnaez, J., F. Gómez und S. Caserío. „Pediatric donation after controlled cardiac death (Maastricht type III donors)“. Medicina Intensiva (English Edition) 41, Nr. 6 (August 2017): 386. http://dx.doi.org/10.1016/j.medine.2016.10.009.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Beato Garcia, S., M. Fiol, B. Etcheverry, L. Riera, J. F. Suárez, S. Gil-Vernet und F. Vigués. „Kidneys from Maastricht category III: Does NECMO influence on DGF?“ European Urology Supplements 17, Nr. 2 (März 2018): e1756-e1757. http://dx.doi.org/10.1016/s1569-9056(18)32069-4.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Corral, E., J. Maynar, I. Saralegui und A. Manzano. „Donantes a corazón parado tipo III de Maastricht: una opción real“. Medicina Intensiva 35, Nr. 1 (Januar 2011): 59–60. http://dx.doi.org/10.1016/j.medin.2010.09.004.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Rubio, J. J., und D. Palacios. „Reflections upon donation after controlled cardiac death (Maastricht type iii donors)“. Medicina Intensiva (English Edition) 40, Nr. 7 (Oktober 2016): 431–33. http://dx.doi.org/10.1016/j.medine.2016.04.007.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Fernandez-Concha Schwalb, J., B. Etcheverry, L. Riera, M. Fiol, X. Bonet, J. F. Suárez, O. Bestard und F. Vigués. „Maastricht III kidneys: Does donor age influence DGF or graft survival?“ European Urology Supplements 18, Nr. 1 (März 2019): e1643-e1644. http://dx.doi.org/10.1016/s1569-9056(19)31193-5.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

CORRAL, JUDITH MARIN, IRENE DOT JORDANA, JUDIT BONCOMPTE TORRES, MARINA BOGUÑÁ, ANA ZAPATERO, YOLANDA DIAZ, M. PILAR GRACIA ARNILLAS et al. „VENTILATOR-INDUCED DIAPHRAGM DYSFUNCTION IN BRAIN-DEAD AND MAASTRICHT III DONORS“. Chest 154, Nr. 4 (Oktober 2018): 1122A—1123A. http://dx.doi.org/10.1016/j.chest.2018.08.1015.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Rubio, J. J., und D. Palacios. „Reflexiones sobre la donación en asistolia controlada (donantes tipo III de Maastricht)“. Medicina Intensiva 40, Nr. 7 (Oktober 2016): 431–33. http://dx.doi.org/10.1016/j.medin.2016.04.003.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Barber Ansón, M., A. N. García Herrera, J. Roldán Ramírez, M. Loinaz Bordonabe, I. Osés Munárriz und A. Orera Pérez. „Combined Thorax-Abdomen Extraction in Controlled Cardiac Death (Maastricht Type III) Donors“. Transplantation Proceedings 51, Nr. 9 (November 2019): 3037–39. http://dx.doi.org/10.1016/j.transproceed.2019.08.020.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Nau, Jean-Yves. „Prélèvement d’organes : la France rejoint les pays autorisant les cas «Maastricht III»“. Revue Médicale Suisse 10, Nr. 455 (2014): 2434–35. http://dx.doi.org/10.53738/revmed.2014.10.455.2434.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

GARDINER, DALE, und ROBERT SPARROW. „Not Dead Yet: Controlled Non-Heart-Beating Organ Donation, Consent, and the Dead Donor Rule“. Cambridge Quarterly of Healthcare Ethics 19, Nr. 1 (22.12.2009): 17–26. http://dx.doi.org/10.1017/s0963180109990211.

Der volle Inhalt der Quelle

Annotation:

The emergence of controlled, Maastricht Category III, non-heart-beating organ donation (NHBD) programs has the potential to greatly increase the supply of donor solid organs by increasing the number of potential donors. Category III donation involves unconscious and dying intensive care patients whose organs become available for transplant after life-sustaining treatments are withdrawn, usually on grounds of futility. The shortfall in organs from heart-beating organ donation (HBD) following brain death has prompted a surge of interest in NHBD. In a recent editorial, the British Medical Journal described NHBD as representing “a challenge which the medical profession has to take up.”

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Martinez, M. Sevilla, A. Iglesias Santiago, R. Lara Rosales, E. P. Fuentes Garcia und J. M. Perez Villares. „Interhospital Transfers of a Mobile Extracorporeal Membrane Oxygenation Team for Maastricht III Donations“. Transplantation Proceedings 51, Nr. 9 (November 2019): 3042–43. http://dx.doi.org/10.1016/j.transproceed.2019.08.013.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Marín-Gómez, Luis M., Gonzalo Suárez-Artacho, Javier Padillo-Ruiz und Miguel A. Gómez-Bravo. „Trasplante hepático dominó con injerto procedente de donante en muerte circulatoria (Maastricht III)“. Cirugía Española 97, Nr. 10 (Dezember 2019): 605–7. http://dx.doi.org/10.1016/j.ciresp.2019.01.013.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

Casanova, Daniel, Federico Castillo und Eduardo Miñambres. „Multiorgan retrieval and preservation of the thoracic and abdominal organs in Maastricht III donors“. World Journal of Transplantation 12, Nr. 5 (18.05.2022): 83–87. http://dx.doi.org/10.5500/wjt.v12.i5.83.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

Mesnard, B., D. Cantarovich, L. Martin-Lefevre, J. Rigaud, G. Blancho, G. Karam, L. Badet, C. Antoine und J. Branchereau. „First French combined kidney/pancreas transplantation from controlled donation after circulatory arrest (Maastricht III)“. Progrès en Urologie 32, Nr. 1 (Januar 2022): 1–2. http://dx.doi.org/10.1016/j.purol.2021.10.001.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Oniscu, G. C., A. Siddique und J. Dark. „Dual Temperature Multi-Organ Recovery From a Maastricht Category III Donor After Circulatory Death“. American Journal of Transplantation 14, Nr. 9 (23.07.2014): 2181–86. http://dx.doi.org/10.1111/ajt.12808.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Malfertheiner, P., F. Megraud, C. O'Morain, F. Bazzoli, E. El-Omar, D. Graham, R. Hunt, T. Rokkas, N. Vakil und E. J. Kuipers. „Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report“. Gut 56, Nr. 6 (01.06.2007): 772–81. http://dx.doi.org/10.1136/gut.2006.101634.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Robert, René, und Benoît Pain. „Prélèvements d’organe selon la procédure Maastricht III : nos garde-fous éthiques sont-ils suffisants ?“ Médecine Intensive Réanimation 29, Nr. 1 (01.03.2020): 3–6. http://dx.doi.org/10.37051/mir-00002.

Der volle Inhalt der Quelle

Annotation:

La pratique de prélèvement d’organe selon la procédure dite Maastricht III (MIII) est l’objet de discussions et de controverses éthiques. Au premier plan de ces craintes, est celle de la dérive utilitariste privilégiant une éthique sociétale àune éthique individuelle. On peut proposer néanmoins un certain nombre de garde-fous éthiques discutés dans cetarticle et dont les principaux sont les suivants : le MIII ne doit pas être la solution unique face à la pénurie de greffons.Les décisions de limitation et arrêt thérapeutique doivent être strictement appliquées dans le cadre de la loi ClaeysLeonetti sans interférence avec l’équipe de prélèvement ; un consentement explicite est la garantie du respect de lavolonté du donneur ; les procédures de sédation accompagnant l’arrêt des traitements de support vitaux doivent êtreidentiques qu’il y ait ou non de prélèvement MIII.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Moal, Valérie, und Corinne Antoine. „Transplantation rénale avec donneurs de la catégorie III de Maastricht, état des lieux en France“. Soins 63, Nr. 826 (Juni 2018): 36–38. http://dx.doi.org/10.1016/j.soin.2018.04.010.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Cámara Moreno, C., A. Francés Comalat, M. J. Pérez Sáez, S. Henao Macaya, A. Zapatero Ferrándiz, J. M. Abascal Junquera, Ll Fumadó Ciutat, J. Pascual Santos und Ll Cecchini Rosell. „75 Early results of a controlled non-heart-beating kidney donor programme (Maastricht type III)“. European Urology Supplements 15, Nr. 3 (März 2016): e75. http://dx.doi.org/10.1016/s1569-9056(16)60077-5.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Rubio-Muñoz, J. J., M. Pérez-Redondo, S. Alcántara-Carmona, I. Lipperheide-Vallhonrat, I. Fernández-Simón, M. Valdivia-de la Fuente, H. Villanueva-Fernández et al. „Protocolo de donación tras la muerte cardiaca controlada (donante tipo iii de Maastricht). Experiencia inicial“. Medicina Intensiva 38, Nr. 2 (März 2014): 92–98. http://dx.doi.org/10.1016/j.medin.2013.01.002.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

Barret, Juan P., Cristina Dopazo, Alberto Sandiumenge, Itxarone Bilbao und Ramón Charco. „Full-Face Allograft Retrieval in a Multiple-Organ Donation in a Maastricht III Type Donor“. Journal of Clinical Medicine 14, Nr. 5 (02.03.2025): 1682. https://doi.org/10.3390/jcm14051682.

Der volle Inhalt der Quelle

Annotation:

Background: Donation after circulatory death (DCD) has emerged as a potential source of transplantable organs. To date, there have been no reports of face procurement in AD, and “face first” with ex situ perfusion has become the gold standard technique for obtaining facial allografts in most centres. Objectives: We report a case of successful total face and kidney transplantation from a 47-year-old male AD donor. Methods: Immediately after confirmation of death, the “rapid recovery” technique was performed and a cannula was placed in the ascending aorta for in situ perfusion of the facial allograft simultaneously with the abdominal team. Results: The total ischaemic time from donor cardiac death to face reperfusion in the recipient was 5.5 h. Excellent renal and facial allograft function was reported.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Coello, Iris, Ana Isabel Martínez, Maria Peraire, Laura Aizpiri, Camila Andrea Vega, Miquel Amer, Ricardo José Guldris, Jose Luis Bauza und Enrique C. Pieras. „Effect of Ischemia Times and Donor and Recipient Features on Maastricht Category III Kidney Transplant Outcomes“. Archivos Españoles de Urología 75, Nr. 7 (2022): 612. http://dx.doi.org/10.56434/j.arch.esp.urol.20227507.88.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Petit, V., F. Provot, R. Lenain und M. Hazzan. „Transplantation rénale à partir de donneurs décédés à cœur arrêté contrôlés dit Maastricht III : l’expérience lilloise“. Néphrologie & Thérapeutique 17, Nr. 5 (September 2021): 307. http://dx.doi.org/10.1016/j.nephro.2021.07.157.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

Marín-Gómez, Luis M., Gonzalo Suárez-Artacho, Javier Padillo-Ruiz und Miguel A. Gómez-Bravo. „Successful Domino Liver Transplantation Using a Graft From a Controlled Donation After Circulatory Death (Maastricht III)“. Cirugía Española (English Edition) 97, Nr. 10 (Dezember 2019): 605–7. http://dx.doi.org/10.1016/j.cireng.2019.07.010.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Oto, Takahiro, Bronwyn Levvey, Robin McEgan, Andrew Davies, David Pilcher, Trevor Williams, Silvana Marasco, Franklin Rosenfeldt und Gregory Snell. „A Practical Approach to Clinical Lung Transplantation From a Maastricht Category III Donor With Cardiac Death“. Journal of Heart and Lung Transplantation 26, Nr. 2 (Februar 2007): 196–99. http://dx.doi.org/10.1016/j.healun.2006.11.599.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Salmeron-Rodriguez, M. D., M. D. Navarro-Cabello, M. L. Agüera-Morales, M. Lopez-Andreu, A. Rodriguez-Benot, J. C. Robles-Arista, J. M. Dueñas-Jurado, J. P. Campos-Hernandez, M. J. Requena-Tapia und P. Aljama-Garcia. „Short-Term Evolution of Renal Transplant With Grafts From Donation After Cardiac Death: Type III Maastricht Category“. Transplantation Proceedings 47, Nr. 1 (Januar 2015): 23–26. http://dx.doi.org/10.1016/j.transproceed.2014.11.012.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Alcantara Carmona, S., N. Martínez Sanz, B. Lobo Valbuena, J. Palamidessi Domínguez, R. Fernández Rivas, M. Pérez Redondo, M. Valdivia de la Fuente, B. Balandín Moreno und JJ Rubio Muñoz. „CHANGES IN ORGAN DONATIONS AFTER THE IMPLEMENTATION OF A CONTROLLED CARDIAC DEATH (MAASTRICHT TYPE III) DONATION PROTOCOL“. Intensive Care Medicine Experimental 3, Suppl 1 (2015): A896. http://dx.doi.org/10.1186/2197-425x-3-s1-a896.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

González-Méndez, M. Isabel, und Luís López-Rodríguez. „Organ donation after controlled cardiac death under Maastricht category iii: Ethical implications and end of life care“. Enfermería Clínica (English Edition) 29, Nr. 1 (Januar 2019): 39–46. http://dx.doi.org/10.1016/j.enfcle.2017.10.009.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

Soussi, David, Xavier Rod, Raphael Thuillier, Suzanne Leblanc, Jean-Michel Goujon, Benoit Barrou, Thierry Hauet und Thomas Kerforne. „Preclinical Modeling of DCD Class III Donation: Paving the Way for the Increased Use of This Challenging Donor Type“. BioMed Research International 2019 (03.09.2019): 1–9. http://dx.doi.org/10.1155/2019/5924101.

Der volle Inhalt der Quelle

Annotation:

Deceased after circulatory death (DCD) donors offer a viable solution to the current organ shortage, particularly the Maastricht Class III (arrest subsequent to cessation of life support in the hospital). Although current results from these donors are very satisfactory, the number of included donors is too low and future expansion of inclusion criteria will likely decrease organ quality, with negative consequences on the complication rate. This donor type thus represents a priority in terms of scientific exploration, so as to study it in controlled settings and prepare for future challenges. Hence, we mimicked the DCD Class III clinical conditions a Large White pig model. Herein, we detail the different strategies attempted to attain our objectives, including technical approaches such as animal positioning and ventilator settings, as well as pharmacological intervention to modulate blood pressure and heart rate. We highlight the best combination of factors to successfully reproduce DCD Class III conditions, with perfusion pressures and functional warm ischemia (hypoperfusion) closely resembling clinical situations. Finally, we detail the functional and histological impacts of these conditions. Such a model could be of critical value to explore novel management alternative for these donors, presenting a uniquely adapted platform for such therapeutics as normothermic regional circulation and/or pharmacological intervention.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

Durand, Guillaume, Maud Jonas, Julien Lorber, Gérard Dabouis und Daniel Villers. „Faisabilité et questionnement éthique du prélèvement d'organes et de tissus sur des donneurs de catégorie III de Maastricht“. Journal International de Bioéthique 25, Nr. 4 (2014): 113. http://dx.doi.org/10.3917/jib.254.0113.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Rubio, J. J., I. Fernández, A. Ortega, I. Lipperheide, M. Pérez und R. Siljeström. „Donación tras la muerte cardiaca controlada (tipo iii de Maastricht). La cirugía rápida sin canulación premorten como alternativa“. Medicina Intensiva 36, Nr. 9 (Dezember 2012): 658–59. http://dx.doi.org/10.1016/j.medin.2012.03.008.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Lallemant, F., D. Dorez und M. Videcoq. „Prélèvements d’organes sur donneurs décédés après arrêt circulatoire de la catégorie III de Maastricht en France en 2015“. Réanimation 25, Nr. 4 (10.06.2016): 382–90. http://dx.doi.org/10.1007/s13546-016-1206-3.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

McInnes, Iain B., Lluís Puig, Alice B. Gottlieb, Christopher T. Ritchlin, Michael Song, Yin You, Shelly Kafka, G. James Morgan, Proton Rahman und Arthur Kavanaugh. „Association Between Enthesitis and Health-related Quality of Life in Psoriatic Arthritis in Biologic-naive Patients from 2 Phase III Ustekinumab Trials“. Journal of Rheumatology 46, Nr. 11 (01.04.2019): 1458–61. http://dx.doi.org/10.3899/jrheum.180792.

Der volle Inhalt der Quelle

Annotation:

Objective.Evaluate enthesitis, physical function, and health-related quality of life (HRQOL) among patients with psoriatic arthritis (PsA) who are naive to anti–tumor necrosis factor agents.Methods.In PSUMMIT 1 and 2, patients with PsA were randomized to placebo or ustekinumab 45 mg or 90 mg. Enthesitis was assessed at weeks 0 and 24 (Maastricht Ankylosing Spondylitis Enthesitis Score). Assessments included Health Assessment Questionnaire–Disability Index (HAQ-DI), Medical Outcomes Study Short Form-36 (SF-36) physical component summary/mental component summary (PCS/MCS), and American College of Rheumatology 20 (ACR20).Results.At Week 24, 21 had worsened enthesitis, 158 had improved enthesitis, and 412 had unchanged enthesitis. Improved enthesitis was associated with improvements in HAQ-DI and SF-36 MCS. Results were similar for ACR20 responders and nonresponders.Conclusion.Improvement in enthesitis at Week 24 was associated with improvements in physical function/HRQOL regardless of ACR20 response.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Drouin, S., M. Raux, J. Tourret, G. Lebreton, G. Coffin, J. Cohen, N. Arzouk et al. „Transplantation rénale issue de donneurs décédés d’arrêt cardiaque de la catégorie III de Maastricht. Résultats après un an d’expérience“. Progrès en Urologie 26, Nr. 13 (November 2016): 709. http://dx.doi.org/10.1016/j.purol.2016.07.086.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Rouzeau, C., E. Lecomte, A. Cailleton, M. Cornuault, C. Boulinguiez, P. Labourot, J. Reignier und C. Guitton. „Prélèvements multiorganes de type Maastricht III en médecine intensive–réanimation. Organisation et retour d’expérience paramédicale dans un service pilote“. Médecine Intensive Réanimation 27, Nr. 1 (Januar 2018): 80–85. http://dx.doi.org/10.3166/rea-2018-0011.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Erhart, Szilárd. „Ready or not? Constructing the Monetary Union Readiness Index“. Journal of Central Banking Theory and Practice 11, Nr. 1 (01.01.2022): 23–66. http://dx.doi.org/10.2478/jcbtp-2022-0002.

Der volle Inhalt der Quelle

Annotation:

Abstract While all EU Member States can join the group's monetary union, the euro area, some members are far more ready for the adoption and use of the single European currency. Here, we construct a new Monetary Union Readiness Index (MURI) for the EU Member States. The theoretical framework of the index is built on the economic theory of Optimal Currency Areas and EU regulations such as the Treaty and the Maastricht criteria, and the Regulation on the Macroeconomic Imbalance Procedure. The index measures (i) nominal convergence, (ii) real convergence, and (iii) macroeconomic stability. The MURI Index provides an easy to use real-time policy tool to evaluate both candidate and current euro area members. Hence, it complements, aggregates and communicates key information in annual convergence reports and in official statistics. Our evaluation finds that Austria, Finland, Denmark, Sweden and Germany showed the highest level of compliance with the different euro area criteria in 2018, while Greece, Cyprus, Romania, Spain, and Italy were the least compliant.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

Verbeek, Hilde, S. M. G. Zwakhalen, J. M. G. A. Schols, G. I. J. M. Kempen und J. P. H. Hamers. „The Living Lab in Ageing and Long-Term Care: A Sustainable Model for Translational Research Improving Quality of Life, Quality of Care and Quality of Work“. Journal of nutrition, health & aging 24, Nr. 1 (25.10.2019): 43–47. http://dx.doi.org/10.1007/s12603-019-1288-5.

Der volle Inhalt der Quelle

Annotation:

Abstract There is a strong need in long-term care for scientific research, so older people and their families, health care professionals, policy makers, and educators can benefit from new advancements and best available evidence in every day care practice. This paper presents the model of a sustainable and successful interdisciplinary collaboration between scientists, care providers and educators in long-term care: the “Living Lab in Ageing and Long-Term Care” by Maastricht University in the Netherlands. Its mission is to contribute with scientific research to improving i) quality of life of older people and their families; ii) quality of care and iii) quality of work of those working in long-term care. Key working mechanisms are the Linking Pins and interdisciplinary partnership using a team science approach, with great scientific and societal impact. A blueprint for the model is discussed, describing its business model and challenges in getting the model operational and sustainable are discussed.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Kaminska, I. V. „Court of Justice of the European Union: historiography of European sources published in the period 1957-1992“. INTERPRETATION OF LAW: FROM THE THEORY TO THE PRACTICE, Nr. 12 (2021): 292–99. http://dx.doi.org/10.33663/2524-017x-2021-12-49.

Der volle Inhalt der Quelle

Annotation:

Before proceeding to the analysis and characterization of foreign publications, all the sources we found were systematized according to the time criterion, according to which all the publications found, which in one way or another examined the Court of Justice, we divided into three periods, namely: I period (1957–1992); II period (1992–2007); III period (2007-present). The division was based on the periodization of the development of European integration, or rather its main stages. And the period – the creation and functioning of the European Communities (from the Treaties of Rome to the signing of the Maastricht Treaty); II period – the formation of the European Union (signing of the Maastricht, Amsterdam, Nice treaties); Period III – the functioning of the European Union in its modern form (after the signing of the Lisbon Treaty and until now). Thanks to this systematization, we were able to demonstrate what topics were relevant among scholars in a particular period of development of integration and functioning of the Court of Justice. The main presentation of the material is devoted to the results of the analysis of foreign scientific publications concerning the principles of organization and functioning of the Court of Justice published in the period 1957–1992. We found that most scientific papers were published by scientists from Great Britain, Italy, Belgium, Luxembourg, Germany, France which account for a significant share of the work of judges and Advocates-General of the Court of Justice. All foreign sources published in this period were analyzed by us on the subject of research and grouped by subject. Thus, we found that in the period 1957–1992.current research topics on the Court of Justice of the EU were: protection of individuals in the EU law and order; methods of interpretation in the decision of the Court of Justice of the EU; judicial control in the EU; the legal nature of the interaction between national judicial institutions and the Court of Justice and their impact on the uniform application of the Community legal order and its organic combination with the national legal order; judicial activism; principles of EU law; the role of EU judges in the development of European integration. Keywords: EU Court, judicial activism, EU legal order, principles of EU law, EU court decision.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

Martouzet, Sara. „Vertus et limites des imaginaires autour des protocoles de fin de vie associés aux prélèvements d’organes de type Maastricht III“. Revue française d'éthique appliquée N° 12, Nr. 1 (13.06.2022): 69–86. http://dx.doi.org/10.3917/rfeap.012.0069.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Favi, Evaldo, Carmelo Puliatti, Samuele Iesari, Andrea Monaco, Mariano Ferraresso und Roberto Cacciola. „Impact of Donor Age on Clinical Outcomes of Primary Single Kidney Transplantation From Maastricht Category-III Donors After Circulatory Death“. Transplantation Direct 4, Nr. 10 (Oktober 2018): e396. http://dx.doi.org/10.1097/txd.0000000000000835.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Lanchon, C., J. A. Long, G. Boudry, N. Terrier, O. Skowron, L. Badet, J. L. Descotes et al. „Transplantation rénale à partir d’un donneur décédé par arrêt circulatoire Maastricht III : première expérience française et revue de la littérature“. Progrès en Urologie 25, Nr. 10 (September 2015): 576–82. http://dx.doi.org/10.1016/j.purol.2015.06.005.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Iyer, A., M. Harkess, A. Havryk, M. Plit, M. Malouf, P. Jansz, E. Granger, K. Dhital, P. Spratt und A. R. Glanville. „271 Non Heparinisation Does Not Impair Outcome of Lung Transplantation from Maastricht Category III Donation after Circulatory Death (DCD) Donors“. Journal of Heart and Lung Transplantation 31, Nr. 4 (April 2012): S98. http://dx.doi.org/10.1016/j.healun.2012.01.278.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

González-Méndez, M. Isabel, und Luís López-Rodríguez. „La donación de órganos en asistolia controlada tipo iii de Maastricht: implicaciones éticas y cuidados al final de la vida“. Enfermería Clínica 29, Nr. 1 (Januar 2019): 39–46. http://dx.doi.org/10.1016/j.enfcli.2017.10.009.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

Schett, Georg, Xenofon Baraliakos, Filip Van den Bosch, Atul Deodhar, Mikkel Østergaard, Ayan Das Gupta, Shephard Mpofu et al. „Secukinumab Efficacy on Enthesitis in Patients With Ankylosing Spondylitis: Pooled Analysis of Four Pivotal Phase III Studies“. Journal of Rheumatology 48, Nr. 8 (15.03.2021): 1251–58. http://dx.doi.org/10.3899/jrheum.201111.

Der volle Inhalt der Quelle

Annotation:

ObjectiveTo assess the efficacy of secukinumab on axial and peripheral enthesitis in patients with ankylosing spondylitis (AS) using pooled data from randomized controlled phase III studies.MethodsIn this posthoc analysis, data were pooled from patients originally randomized to secukinumab 150 mg, 300 mg, or placebo (PBO) from phase III MEASURE 1–4 studies (ClinicalTrials.gov: NCT01358175, NCT01649375, NCT02008916, and NCT02159053). Maastricht AS Enthesitis Score (MASES) was used for assessments of enthesitis through Week 52. Efficacy outcomes were mean change in MASES score and complete resolution (MASES = 0) of enthesitis in patients with baseline MASES > 0.ResultsA total of 693 (71.5%) patients had enthesitis at baseline in secukinumab 300 mg, 150 mg, and PBO groups (58 [76.3%], 355 [70.4%], and 280 [72%], respectively) out of 969 patients pooled in this analysis. At Week 16, mean changes from baseline for overall MASES and enthesitis at axial MASES sites, respectively, were as follows: –2.9 (P < 0.01) and –2.9 (P < 0.01) for secukinumab 300 mg; –2.4 (P < 0.015) and –2.3 (P < 0.05) for secukinumab 150 mg; and –1.9 and –1.8 for PBO, with improvements seen through Week 52. More than one-third of secukinumab-treated patients (300 mg: 36.2%; 150 mg: 40.8%) achieved complete resolution of enthesitis at Week 16.ConclusionSecukinumab improved enthesitis at overall MASES and axial sites in patients with AS.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

Park, Hoonsung, Eun-Sil Jung, Jae-Sook Oh, Yong-Min Lee und Jae-Myeong Lee. „Organ donation after controlled circulatory death (Maastricht classification III) following the withdrawal of life-sustaining treatment in Korea: a suggested guideline“. Korean Journal of Transplantation 35, Nr. 2 (30.06.2021): 71–76. http://dx.doi.org/10.4285/kjt.21.0004.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!